Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose With MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults

NCT05216601 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.

NCT NCT05216601
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216601 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose With MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults
Lead sponsor
Medigen Vaccine Biologics Corp.
Phase
Phase 1
Overall status
Completed
Start date
May 6, 2022
Completion date
November 30, 2022
Enrollment
107 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 vaccine